Physician profile
Catherine Singiser
NPI 1265037717
$941.89
in general payments reported to CMS, 2019-2025
13 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $33.51 · 2024: $614 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $216.74 | 2023-2025 | |
| Janssen Biotech, INC. | $145.85 | 2024-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.09 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $90.34 | 2024 | Entyvio |
| Madrigal Pharmaceuticals | $72.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $50.26 | 2024-2025 | |
| Daiichi Sankyo INC. | $47.61 | 2025 | Injectafer |
| Braintree Laboratories, INC. | $46.70 | 2024 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $44.80 | 2024-2025 | Voquezna |
| Genzyme Corporation | $39.82 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $20.87 | 2024 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $18.93 | 2024 | Dupixent |
| Celltrion USA INC. | $15.75 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Singiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.